Huang Yiying, Hoque Md Tozammel, Jenabian Mohammad-Ali, Vyboh Kishanda, Whyte Sana-Kay, Sheehan Nancy L, Brassard Pierre, Bélanger Maud, Chomont Nicolas, Fletcher Courtney V, Routy Jean-Pierre, Bendayan Reina
Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada.
Department of Biological Sciences, Université du Québec à Montréal (UQAM), Montréal, Canada.
J Antimicrob Chemother. 2016 Jul;71(7):1954-65. doi: 10.1093/jac/dkw046. Epub 2016 Apr 13.
The testes are a potential viral sanctuary site for HIV-1 infection. Our study aims to provide insight into the expression and localization of key drug transporters and metabolic enzymes relevant to ART in this tissue compartment.
We characterized gene and protein expression of 12 representative drug transporters and two metabolic enzymes in testicular tissue samples obtained from uninfected (n = 8) and virally suppressed HIV-1-infected subjects on ART (n = 5) and quantified antiretroviral drug concentrations in plasma and testicular tissues using LC/MS/MS from HIV-1-infected subjects.
Our data demonstrate that key ABC drug transporters (permeability glycoprotein, multidrug-resistance protein 1, 2 and 4, and breast cancer resistance protein), solute carrier transporters (organic anion transporting polypeptides 1B1 and 2B1, organic anion transporter 1, concentrative nucleoside transporter 1, equilibrative nucleoside transporter 2) and cytochrome P450 metabolic enzymes (CYP3A4 and CYP2D6) previously shown to interact with many commonly used antiretroviral drugs are expressed at the mRNA and protein level in the testes of both subject groups and localize primarily at the blood-testis barrier, with no significant differences between the two groups. Furthermore, we observed that PIs known to be substrates for ATP-binding cassette membrane transporters, displayed variable testicular tissue penetration, with darunavir concentrations falling below therapeutic values. In contrast, the NRTIs emtricitabine, lamivudine and tenofovir displayed favourable tissue penetration, reaching concentrations comparable to plasma levels. We also demonstrated that nuclear receptors, peroxisome proliferator-activated receptors α and γ exhibited higher gene expression in the testicular tissue compared with pregnane X receptor and constitutive androstane receptor, suggesting a potential regulatory pathway governing drug transporter and metabolic enzyme expression in this tissue compartment.
Our data suggest the testes are a complex pharmacological compartment that can restrict the distribution of certain antiretroviral drugs and potentially contribute to HIV-1 persistence.
睾丸是HIV-1感染潜在的病毒庇护场所。我们的研究旨在深入了解该组织区室中与抗逆转录病毒治疗(ART)相关的关键药物转运体和代谢酶的表达及定位。
我们对从未感染(n = 8)以及接受ART治疗且病毒得到抑制的HIV-1感染受试者(n = 5)获取的睾丸组织样本中的12种代表性药物转运体和两种代谢酶的基因及蛋白表达进行了表征,并使用LC/MS/MS对HIV-1感染受试者的血浆和睾丸组织中的抗逆转录病毒药物浓度进行了定量。
我们的数据表明,先前显示与许多常用抗逆转录病毒药物相互作用的关键ABC药物转运体(通透性糖蛋白、多药耐药蛋白1、2和4以及乳腺癌耐药蛋白)、溶质载体转运体(有机阴离子转运多肽1B1和2B1、有机阴离子转运体1、浓缩核苷转运体1、平衡核苷转运体2)和细胞色素P450代谢酶(CYP3A4和CYP2D6)在两组受试者的睾丸中均在mRNA和蛋白水平表达,且主要定位于血睾屏障,两组之间无显著差异。此外,我们观察到已知为ATP结合盒膜转运体底物的蛋白酶抑制剂在睾丸组织中的穿透性各异,达芦那韦浓度低于治疗值。相比之下,核苷类逆转录酶抑制剂恩曲他滨、拉米夫定和替诺福韦显示出良好的组织穿透性,达到与血浆水平相当的浓度。我们还证明,与孕烷X受体和组成型雄甾烷受体相比,核受体过氧化物酶体增殖物激活受体α和γ在睾丸组织中表现出更高的基因表达,提示在该组织区室中存在一条潜在的调控药物转运体和代谢酶表达的途径。
我们的数据表明,睾丸是一个复杂的药理学区室,可限制某些抗逆转录病毒药物的分布,并可能导致HIV-1持续存在。